Antibody formulations

Abstract

The present invention relates to formulations comprising sucrose, and methods of making such formulations, wherein the sucrose content promotes the reduction or elimination of the reversible self-association (RSA) tendency of the antibody in the formulation. The present invention also relates to formulations comprising an anti-PDGFR-alpha antibody or antibody fragment. Such antibodies can be used in various methods of treatment. The application further relates to a method of eliminating or reducing the RSA tendency of antibodies in a formulation.

Description

RELATED APPLICATIONS[0001]This application claims the benefit of U.S. provisional application 61 / 361,209, filed Jul. 2, 2010. The disclosure of the foregoing application is hereby incorporated by reference in its entirety.SEQUENCE LISTING [0002]The instant application contains a Sequence Listing which has been concurrently submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jun. 24, 2011, is named 12728101.txt and is 3,275 bytes in size.BACKGROUND OF THE INVENTION[0003]Instability and / or presence of undesirable species in an antibody formulation may pose problems including simple inconvenience, such as the need to store or handle the formulation in a particular way, and safety and efficacy concerns, such as those caused by increased toxicity or immunogenicity. One characteristic that is observed with some antibodies is the tendency for the antibody molecules to self-associate reversibly, also known as reversible ...

AI Technical Summary

Benefits of technology

[0005]The present disclosure provides formulation methodology for reducing reversible self-association of an antibody or antibody fragment in a formulation. As such, the present disclosure provides methods that can be used to identify improved formulations for preparing antibodies and antibody fragments. Such formulations can be used, for example, therapeutically or diagnostically in a clinical or laboratory setting.

[0017]In certain embodiments of any of the foregoing aspects and embodiments, the formulation is suitable for intravenous administration. In certain embodiments, the aqueous carrier is water. In some embodiments, the formulation is non-pyrogenic. In other embodiments, the formulation further comprises a preservative to extend shelf-life. In some embodiments, the formulation is stable at 2-8° C. for at least 2 years as determined by high performance size exclusion chromatography (HPSEC). In some embodiments, purity of said formulation decreases by less than 0.5% per year for at least two years as determined by high performance size exclusion chromatography (HPSEC).

[0033]In further aspects, the present disclosure provides a method of eliminating or reducing reversible self-association (RSA) of an antibody in a formulation, comprising: providing an initial formulation comprising an antibody or antibody fragment, wherein RSA of said antibody or antibody fragment in said initial formulation is measurable by HPSEC i) at approximately 2-8° C. and / or ii) at a concentration of greater than 4 mg / ml, and which antibody or antibody fragment in said initial formulation contains high molecular weight forms; adding sucrose to said initial formulation to provide an altered formulation having about 4% to about 20% (weight / volume) sucrose, wherein RSA of the antibody or antibody fragment in the altered formulation is eliminated or reduced relative to that of the initial formulation, when compared at a given antibody concentration at approximately 2-8° C.

[0038]In other aspects, the present disclosure provides a method of eliminating or reducing reversible self-association (RSA) of an antibody in a formulation, comprising: a) providing an initial formulation comprising an antibody or antibody fragment, wherein RSA of said antibody or antibody fragment in said initial formulation is detectable by HPSEC at approximately 2-8° C. when assessed at a concentration of 10 mg / ml; b) assaying a biophysical property of said antibody or antibody fragment in said initial formulation using one or more assays; c) adjusting sucrose content of said initial formulation to achieve a final concentration from about 4% to about 20% (w / v) to produce an altered formulation; and d) assaying a biophysical property of said antibody or antibody fragment in said altered formulation using one or more assays; wherein RSA of the antibody or antibody fragment in the altered formulation is eliminated relative to that of the initial formulation, when compared at a given antibody concentration at approximately 2-8° C.

Problems solved by technology

In one embodiment, the liquid formulation is not suitable for lyophilization.

Images